INTRODUCTION TO

CANCER RESEARCH TECHNOLOGY AND CANCER RESEARCH UK

International Cancer Cluster Showcase – BIO 2014

June 2014

ADVANCING DISCOVERIES TO BEAT CANCER

2

CRT PROVIDES A GATEWAY TO HIGH-QUALITY ONCOLOGY RESEARCH

CRUK FUNDED UNIVERSITIES

CRUK CENTRES

CRUK INSTITUTES

CRUK Cancer Cluster:•Network of institutes• Universities• 18 ECMC

• Plus: Infrastructure, training and IP framework• Partners: CRUK, Universities, Dept of Health, NHS

3

Cancer Research Technology Cancer Research UK

• Technology development and commercialisation arm of CRUK

• Exclusive rights to IP from CRUK funded research

• HQ in London, US subsidiary in Boston, partner in Australian consortium

• Provide commercialisation services to oncology institutions worldwide

• World's largest charitable funder of cancer research

• Employs its own scientists and funds research in UK universities

• Entirely funded by donations from the public

• Annual research spend of more than $500 million

• Partnerships with more than 20 charities and academic institutes

WHO WE ARE

New Strategy: bold ambition of three-quarters of patients survive the disease within next 20 yrs (aiming to invest £2b over next 5 yrs)

4

30 agents in preclinical and clinical in development

7 successful drugs

Zytiga for prostate cancer

Temodar for brain cancer

Etopophos for lymphoma, sarcoma, leukaemia, lung, brain and testicular cancers

Alimta for lung cancer

Lentaron for breast cancer

Zinecard or Savene for reducing chemotherapy side effects

Lozoxantrone for leukaemia

5

MODELS – DIFFERENT APPROACHES FOR DIFFERENT PROJECTS

R+D Collaborations

Consortia

Alliances

CRT Pioneer Fund

Clinical Development

In the last 5 years, CRT have signed

>60 agreements in one or more of these models

6

TRANSLATIONAL RESEARCH AND DEVELOPMENTDRUG DISCOVERY – SMALL MOLECULE AND BIOTHERAPEUTICS

• Translational funding– Academic drug discovery units– Response mode funding streams

• CRT Discovery Laboratories (CRTDL)

Over 80 drug discovery programmes under development

Discovery Laboratories

7

ALLIANCES AT CRT’S DISCOVERY LABORATORIES

Cancer Metabolism

signed Jul-20102yr extension Mar-13

Deubiquitinatingenzymes (DUBs)

signed Jul-13

DNA damage repair processes (DDR)

signed Sept-13

Model brings together the best of academia and industry:

World-class CRUK-funded research and PI’s CRTDL’s expertise in validating and progressing new drug targets Company drug research and development capabilities

8

PRECLINICAL & CLINICAL COLLABORATION OPPORTUNITIES

Tap into CRUK’s Experimental Cancer Medicine Centre Network: 18 world class clinical research sites

– CRT/CRUK’s Clinical Development Partnerships program (9 projects to date)

» Runs Phase I/IIa trials of depriorizitized compounds

» Company has first option to license study data

– CRUK’s Experimental Cancer Medicines Centre Combinations Alliance

» Supports industry collaborations with combination studies of novel agents

» 14 studies are underway with AZ, Lilly and Astex

– CRUK’s Stratified Medicine Programme

» Working to establish a national service delivering genetic testing of tumours

» Collaborating with AZ, Pfizer and the UK government‘s Technology Strategy Board

9

SMALL MOLECULES• Inhibitors of CDK7• Chk2 Inhibitor Programme• First in Class IKK Alpha Selective Inhibitors• Inhibitors of Autotaxin• Selective HDAC-2/3 Inhibitors• Inhibitors of LIMK1 and LIMK2• FOXA1 Inhibitors• Selective Inhibitor of Aurora B/C• Cancer Stem Cell Consortium• PAK

BIOLOGICAL THERAPEUTICS• CEA Antibodies• ɑvß6-binding Peptides for Tumour Targeting• ADAM8• MUC1: Naked DNA Cancer Vaccine• S100A4 Neutralising Antibody• sIGF2R-Trap Therapy• ɑvß6 Antagonistic Antibodies• FRMD4A Antibody Target• TACE Antibody• p53 TCR Mimic• CCR4; CCL17/22• c-Met Antibodies• CLEC14a• CD55 Antibodies• CLEC14a CARs

DIAGNOSTICS• Prostate Cancer Prognostic Markers• ɑvß6 Binding Peptides for Imaging• MCM Proteins – Diagnostic Markers for Lung Cancer• Diagnostic Biomarker for Pancreatic Cancer• Predictive Serum Biomarker for Avastin Treatment Decision

ENABLING TECHNOLOGY• High Throughput Leukaemia Initiating Cell Assay• Proximal Kinase Substrate Identification Method• Novel Protein-tag for Radiolabelling of Recombinant

Proteins• Imaging Agent for Prostate and Glioma Tumour Detection

MEDICAL DEVICES• HIFU• Biological Fluid Filtration Device

OTHER OPPORTUNITIES• Amplified FRET-FLIM• Hypoxia Gene Signature• IBIS Software (Tyrer-Cuzick Model)

CRT LICENSING OPPORTUNITIES>$500M in funding yields a large number of projects available for licensing

Thank you… And please come visit

our POSTER!